Bayer announced today that data from several studies across its oncology portfolio will be presented at the 52 Annual Meeting of the American Society of Clinical Oncology , taking place June 3-7 in Chicago. The data represent clinical research on Bayer's oncology products, as well as continued investigation of Xofigo injection in other areas of metastatic castration-resistant prostate cancer .
